|
Gene: HNRNPD |
Gene summary for HNRNPD |
Gene summary. |
Gene information | Species | Human | Gene symbol | HNRNPD | Gene ID | 3184 |
Gene name | heterogeneous nuclear ribonucleoprotein D | |
Gene Alias | AUF1 | |
Cytomap | 4q21.22 | |
Gene Type | protein-coding | GO ID | GO:0000723 | UniProtAcc | Q14103 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3184 | HNRNPD | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.14e-08 | -3.02e-01 | 0.0155 |
3184 | HNRNPD | HTA11_347_2000001011 | Human | Colorectum | AD | 1.61e-04 | 4.65e-01 | -0.1954 |
3184 | HNRNPD | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.92e-03 | 7.94e-01 | 0.0171 |
3184 | HNRNPD | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.24e-05 | 5.56e-01 | 0.294 |
3184 | HNRNPD | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 5.75e-07 | 1.11e+00 | 0.3487 |
3184 | HNRNPD | A001-C-207 | Human | Colorectum | FAP | 9.77e-03 | -4.71e-03 | 0.1278 |
3184 | HNRNPD | A015-C-203 | Human | Colorectum | FAP | 1.47e-33 | -3.58e-01 | -0.1294 |
3184 | HNRNPD | A015-C-204 | Human | Colorectum | FAP | 2.08e-07 | -3.21e-01 | -0.0228 |
3184 | HNRNPD | A014-C-040 | Human | Colorectum | FAP | 1.81e-06 | -4.96e-01 | -0.1184 |
3184 | HNRNPD | A002-C-201 | Human | Colorectum | FAP | 6.86e-17 | -3.51e-01 | 0.0324 |
3184 | HNRNPD | A002-C-203 | Human | Colorectum | FAP | 1.33e-05 | -2.20e-01 | 0.2786 |
3184 | HNRNPD | A001-C-119 | Human | Colorectum | FAP | 5.71e-05 | -2.05e-01 | -0.1557 |
3184 | HNRNPD | A001-C-108 | Human | Colorectum | FAP | 6.57e-16 | -2.46e-02 | -0.0272 |
3184 | HNRNPD | A002-C-205 | Human | Colorectum | FAP | 2.35e-22 | -1.28e-01 | -0.1236 |
3184 | HNRNPD | A001-C-104 | Human | Colorectum | FAP | 2.70e-03 | 2.69e-02 | 0.0184 |
3184 | HNRNPD | A015-C-005 | Human | Colorectum | FAP | 3.46e-02 | -8.34e-02 | -0.0336 |
3184 | HNRNPD | A015-C-006 | Human | Colorectum | FAP | 1.53e-17 | -2.17e-01 | -0.0994 |
3184 | HNRNPD | A015-C-106 | Human | Colorectum | FAP | 1.11e-19 | -3.13e-01 | -0.0511 |
3184 | HNRNPD | A002-C-114 | Human | Colorectum | FAP | 3.20e-20 | -2.67e-01 | -0.1561 |
3184 | HNRNPD | A015-C-104 | Human | Colorectum | FAP | 7.55e-35 | -1.35e-01 | -0.1899 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00712417 | Liver | Cirrhotic | cellular response to inorganic substance | 81/4634 | 226/18723 | 1.21e-04 | 1.20e-03 | 81 |
GO:00510546 | Liver | Cirrhotic | positive regulation of DNA metabolic process | 73/4634 | 201/18723 | 1.60e-04 | 1.52e-03 | 73 |
GO:00011013 | Liver | Cirrhotic | response to acid chemical | 52/4634 | 135/18723 | 2.65e-04 | 2.36e-03 | 52 |
GO:00432002 | Liver | Cirrhotic | response to amino acid | 45/4634 | 116/18723 | 5.54e-04 | 4.36e-03 | 45 |
GO:00322002 | Liver | Cirrhotic | telomere organization | 58/4634 | 159/18723 | 6.31e-04 | 4.82e-03 | 58 |
GO:005105211 | Liver | Cirrhotic | regulation of DNA metabolic process | 114/4634 | 359/18723 | 1.48e-03 | 9.85e-03 | 114 |
GO:00427525 | Liver | Cirrhotic | regulation of circadian rhythm | 45/4634 | 121/18723 | 1.55e-03 | 1.01e-02 | 45 |
GO:00323551 | Liver | Cirrhotic | response to estradiol | 51/4634 | 141/18723 | 1.60e-03 | 1.04e-02 | 51 |
GO:20002787 | Liver | Cirrhotic | regulation of DNA biosynthetic process | 39/4634 | 106/18723 | 3.80e-03 | 2.08e-02 | 39 |
GO:0071229 | Liver | Cirrhotic | cellular response to acid chemical | 31/4634 | 80/18723 | 3.83e-03 | 2.10e-02 | 31 |
GO:190236911 | Liver | Cirrhotic | negative regulation of RNA catabolic process | 29/4634 | 75/18723 | 5.24e-03 | 2.69e-02 | 29 |
GO:0071230 | Liver | Cirrhotic | cellular response to amino acid stimulus | 27/4634 | 71/18723 | 8.90e-03 | 4.11e-02 | 27 |
GO:00454721 | Liver | Cirrhotic | response to ether | 8/4634 | 14/18723 | 9.65e-03 | 4.35e-02 | 8 |
GO:004348911 | Liver | Cirrhotic | RNA stabilization | 25/4634 | 65/18723 | 9.85e-03 | 4.43e-02 | 25 |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
GO:003133122 | Liver | HCC | positive regulation of cellular catabolic process | 295/7958 | 427/18723 | 3.20e-29 | 1.45e-26 | 295 |
GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
GO:004670021 | Liver | HCC | heterocycle catabolic process | 299/7958 | 445/18723 | 2.07e-26 | 7.29e-24 | 299 |
GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
GO:001943921 | Liver | HCC | aromatic compound catabolic process | 309/7958 | 467/18723 | 1.56e-25 | 4.94e-23 | 309 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HNRNPD | SNV | Missense_Mutation | novel | c.103C>A | p.Gln35Lys | p.Q35K | Q14103 | protein_coding | tolerated_low_confidence(0.51) | benign(0) | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
HNRNPD | SNV | Missense_Mutation | c.995N>G | p.Tyr332Cys | p.Y332C | Q14103 | protein_coding | tolerated(0.05) | probably_damaging(0.926) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
HNRNPD | SNV | Missense_Mutation | novel | c.766G>T | p.Val256Leu | p.V256L | Q14103 | protein_coding | tolerated(0.06) | benign(0.05) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HNRNPD | SNV | Missense_Mutation | novel | c.757N>A | p.Glu253Lys | p.E253K | Q14103 | protein_coding | deleterious(0.04) | possibly_damaging(0.842) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
HNRNPD | insertion | Frame_Shift_Ins | novel | c.793_794insT | p.Gln265LeufsTer8 | p.Q265Lfs*8 | Q14103 | protein_coding | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | ||
HNRNPD | SNV | Missense_Mutation | c.1052G>A | p.Ser351Asn | p.S351N | Q14103 | protein_coding | tolerated(1) | possibly_damaging(0.878) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
HNRNPD | SNV | Missense_Mutation | novel | c.565N>A | p.Leu189Ile | p.L189I | Q14103 | protein_coding | deleterious(0.01) | possibly_damaging(0.759) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HNRNPD | SNV | Missense_Mutation | c.528N>C | p.Lys176Asn | p.K176N | Q14103 | protein_coding | deleterious(0.02) | possibly_damaging(0.824) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
HNRNPD | SNV | Missense_Mutation | c.526A>C | p.Lys176Gln | p.K176Q | Q14103 | protein_coding | tolerated(0.05) | benign(0.254) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
HNRNPD | SNV | Missense_Mutation | c.464N>C | p.Met155Thr | p.M155T | Q14103 | protein_coding | deleterious(0.01) | benign(0.138) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |